UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy

被引:7
|
作者
Diaz-Santa, Johana [1 ]
Rodriguez-Romanos, Rocio [1 ]
Osca, Gemma [1 ]
Pratcorona, Marta [2 ]
Garrido, Ana [2 ]
Coll, Rosa [1 ]
Moret, Carla [1 ]
Escoda, Lourdes [3 ]
Tormo, Mar [4 ]
Heras, Inma [5 ]
Arnan, Montse [6 ]
Vives, Susanna [7 ]
Salamero, Olga [8 ]
Lloveras, Natalia [1 ]
Bargay, Joan [9 ]
Sampol, Antonia [10 ]
Cruz, David [1 ]
Garcia, Antoni [11 ]
Quinones, Teresa [1 ]
Esteve, Jordi [12 ]
Sierra, Jorge [2 ]
Gallardo, David [1 ]
机构
[1] Univ Girona, Hematol Dept, Catalan Inst Oncol ICO, Inst Invest Biomed Girona IDIBGI, Girona, Spain
[2] Univ Autonoma Barcelona, Hosp Santa Creu i St Pau, Inst Invest Biomed St Pau, Hematol Dept, Barcelona, Spain
[3] Hosp Joan 23, Hematol Dept, Catalan Inst Oncol ICO, Tarragona, Spain
[4] Hosp Clin, Hematol Dept, Valencia, Spain
[5] Univ Hosp Morales Meseguer, Dept Hematol, Murcia, Spain
[6] Catalan Inst Oncol ICO, Dept Hematol, Barcelona, Spain
[7] Josep Carreras Leukemia Res Inst IJC, Hematol Dept, Catalan Inst Oncol ICO, Barcelona, Spain
[8] Hosp Vall dHebro, Hematol Dept, Barcelona, Spain
[9] Hosp Son Llatzer, Hematol Dept, Palma De Mallorca, Spain
[10] Hosp Son Espases, Hematol Dept, Palma De Mallorca, Spain
[11] Hosp Arnau Vilanova, Hematol Dept, Lleida, Spain
[12] Univ Barcelona, Hematol Dept, Inst Invest Biomed August Pi i Sunyer IDIBAP, Hosp Clin, Barcelona, Spain
关键词
ACUTE MYELOGENOUS LEUKEMIA; POLYMORPHISMS; MUTATIONS; CANCER; ADULTS; IMPACT; GENE; 1A1;
D O I
10.1038/s41375-020-0784-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The treatment of acute myeloid leukemia (AML) is adjusted according to cytogenetic risk factors and molecular markers. Cytarabine remains the main drug to treat AML, and several studies have explored the prognostic relevance of the genotype of cytarabine metabolizing enzymes in AML. Glucuronidation has been identified to be relevant in the cytarabine clearance, but there are still few data concerning the clinical impact of genetic polymorphisms known to condition the activity of UDP-glucuronosyl transferases in AML patients. Here we report the association between the UGT1A1 rs8175347 genotype and the clinical outcome of 455 intermediate-risk cytogenetic AML patients receiving cytarabine-based chemotherapy. Patients with the UGT1A1*28 homozygous variant (associated to a lower UGT1A1 activity) had a lower overall survival (OS) (25.8% vs. 45.5%;p: 0.004). Multivariate analysis confirmed this association (p: 0.008; HR: 1.79; 95% CI: 1.16-2.76). Subgroup analysis showed the negative effect of the UGT1A1*28 homozygous genotype on OS in women (14.8% vs. 52.7%;p: 0.001) but not in men. This lower OS was associated with longer neutropenia after consolidation chemotherapy and with higher mortality without previous relapse, suggesting an association between a low glucuronidation activity and mortal toxic events.
引用
收藏
页码:2925 / 2933
页数:9
相关论文
共 50 条
  • [1] UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy
    Johana Díaz-Santa
    Rocío Rodríguez-Romanos
    Gemma Osca
    Marta Pratcorona
    Ana Garrido
    Rosa Coll
    Carla Moret
    Lourdes Escoda
    Mar Tormo
    Inma Heras
    Montse Arnan
    Susanna Vives
    Olga Salamero
    Natàlia Lloveras
    Joan Bargay
    Antònia Sampol
    David Cruz
    Antoni Garcia
    Teresa Quiñones
    Jordi Esteve
    Jorge Sierra
    David Gallardo
    Leukemia, 2020, 34 : 2925 - 2933
  • [2] THE UGT1A1 GENOTYPE INFLUENCES THE SURVIVAL OF PATIENTS WITH ACUTE MYELOBLASTIC LEUKEMIA OF INTERMEDIATE CITOGENETIC RISK
    Diaz Santa, J.
    Rodriguez Romanos, R.
    Osca Gelis, G.
    Coll Jorda, R.
    Pratcorona, M.
    Moret Puig, C.
    Escoda, L.
    Heras, I
    Arnan, M.
    Vives, S.
    Salamero, O.
    Lloveras Guelquee, N.
    Bargay, J.
    Sampol, A.
    Cruz Garcia, D.
    Garcia, A.
    Quinones, T.
    Sierra, J.
    Esteve, J.
    Tormo, M.
    Tuset Andujar, E.
    Gallardo Giralt, D.
    HAEMATOLOGICA, 2019, 104 : 268 - 269
  • [3] Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens
    Peng Chen
    Ke-Wei Zhu
    Dao-Yu Zhang
    Han Yan
    Han Liu
    Yan-Ling Liu
    Shan Cao
    Gan Zhou
    Hui Zeng
    Shu-Ping Chen
    Xie-Lan Zhao
    Jing Yang
    Xiao-Ping Chen
    Journal of Translational Medicine, 16
  • [4] Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens
    Chen, Peng
    Zhu, Ke-Wei
    Zhang, Dao-Yu
    Yan, Han
    Liu, Han
    Liu, Yan-Ling
    Cao, Shan
    Zhou, Gan
    Zeng, Hui
    Chen, Shu-Ping
    Zhao, Xie-Lan
    Yang, Jing
    Chen, Xiao-Ping
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [5] Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy
    Ravandi, Farhad
    Cortes, Jorge
    Faderl, Stefan
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Santos, Fabio P. S.
    Shan, Jianqin
    Brandt, Mark
    de Lima, Marcos
    Pierce, Sherry
    Kantarjian, Hagop
    BLOOD, 2010, 116 (26) : 5818 - 5823
  • [6] 5′-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics
    Diaz-Santa, Johana
    Rodriguez-Romanos, Rocio
    Coll, Rosa
    Osca, Gemma
    Pratcorona, Marta
    Gonzalez-Bartulos, Marta
    Garrido, Ana
    Angona, Anna
    Talarn, Carme
    Tormo, Mar
    Arnan, Montserrat
    Vives, Susanna
    Salamero, Olga
    Tuset, Esperanza
    Lloveras, Natalia
    Diez, Isabel
    Zamora, Lurdes
    Bargay, Joan
    Sampol, Antonia
    Cruz, David
    Vila, Jordi
    Sitges, Marta
    Garcia, Antoni
    Vall-Llovera, Ferran
    Esteve, Jordi
    Sierra, Jorge
    Gallardo, David
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (06) : 755 - 764
  • [7] Low-Level SAMHD1 Expression in Acute Myeloid Leukemia Blasts Correlates with Favorable Outcome in Patients with Diploid Cytogenetics Treated with Cytarabine-Based Chemotherapy Regimens
    Rassidakis, George
    Nikolas, Herold
    Myrberg, Ida Hed Hed
    Tsesmetzis, Nikolaos
    Grander, Dan
    Kantarjian, Hagop M.
    Medeiros, L. Jeffrey
    Xagoraris, Ioanna
    Khoury, Joseph David
    BLOOD, 2017, 130
  • [8] GLI1 polymorphisms influence remission rate and prognosis of young de novo acute myeloid leukemia patients treated with cytarabine-based chemotherapy
    Liu, Yanfeng
    Liu, Yi
    Chen, Peng
    Chen, Ge
    Chen, Xiaoping
    ANNALS OF HEMATOLOGY, 2024, 103 (06) : 1967 - 1977
  • [9] Improved Outcome of Patients With Low- and Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML) in First Relapse With Gemtuzumab and Cytarabine Versus Cytarabine
    Prebet, Thomas
    Etienne, Anne
    Devillier, Raynier
    Romeo, Emilie
    Charbonnier, Aude
    D'incan, Evelyne
    Esterni, Benjamin
    Arnoulet, Christine
    Blaise, Didier
    Vey, Norbert
    CANCER, 2011, 117 (05) : 974 - 981
  • [10] Polymorphism of UGT1A1 and Frequency of Hyperbilirubinemia in Patients with Chronic Myeloid Leukemia Treated By Nilotinib
    Bykova, Anastasia
    Abdullaev, Adhamjon
    Gusarova, Galina
    Chelysheva, Ekaterina
    Treglazova, Svetlana
    Smirnova, Svetlana
    Turkina, Anna G.
    BLOOD, 2014, 124 (21)